Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular condition with no FDA-approved therapies. The designation is intended to expedite the development and review of drugs targeting serious conditions with unmet medical needs.
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phase 2 trial being conducted at the Tufts Medical Center in Boston, Massachusetts, early, with 17 patients having completed the study.
OKYO Pharma reports long-term shelf stability of corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confirmation that urcosimod remains stable for over two and a half years in single-use ampoules – small, sealed containers designed to hold a single dose of liquid medication – is an important step in bringing the company closer to submitting a successful New Drug Application (NDA) for FDA approval.
OKYO Pharma secures USAN designation ‘urcosimod' for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in developing treatments for unmet medical needs in ophthalmology, such as neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED).
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Research believe. The company is focused on developing OK-101 to treat neuropathic corneal pain (NCP), which has no Food and Drug Administration (FDA)-approved treatment.
OKYO Pharma insiders acquire shares
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company's shares at US$1.04 per share. Additionally, Panetta Partners, in which executive chairman Gabriele Cerrone holds a beneficial interest, purchased 20,000 shares at the same price.
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for the six months ending in September 2024. The company said it expects to complete enrollment of its Phase 2a trial of its investigational therapeutic OK-101 in neuropathic corneal pain (NCP) by the end of the second quarter.
OKYO Pharma secures non-dilutive funding to advance clinical programs
OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing novel therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED), This funding will support the company's ongoing research and development efforts, with a primary focus on advancing its lead program, OK-101, designed to treat NCP, a condition with no FDA-approved therapies.
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference
OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024. Dr Raj Patil, OKYO's chief scientific officer, will present efficacy and safety data from the Phase 2 trial of OK-101, OKYO's leading candidate for treating dry eye disease (DED), on November 2.
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic corneal pain (NCP). Jacob highlighted a significant milestone for the trial: the first patient dosed.
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which is believed to be caused by nerve damage to the cornea combined with inflammation, causes pain and sensitivity of the eyes, face or head.
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's broader efforts to address unmet needs in the billion-dollar inflammatory dry eye disease (DED) market and NCP, an eye condition characterized by severe eye pain and sensitivity with no approved therapies.
